- Home
- SSKN vs PMCB Comparison
SSKN vs PMCB Comparison
Compare SSKN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSKN
- PMCB
- Stock Information
- Founded
- SSKN 1989
- PMCB 1996
- Country
- SSKN United States
- PMCB United States
- Employees
- SSKN N/A
- PMCB N/A
- Industry
- SSKN Medical/Dental Instruments
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSKN Health Care
- PMCB Health Care
- Exchange
- SSKN Nasdaq
- PMCB Nasdaq
- Market Cap
- SSKN 12.5M
- PMCB 11.4M
- IPO Year
- SSKN 2005
- PMCB N/A
- Fundamental
- Price
- SSKN $2.89
- PMCB $1.64
- Analyst Decision
- SSKN
- PMCB
- Analyst Count
- SSKN 0
- PMCB 0
- Target Price
- SSKN N/A
- PMCB N/A
- AVG Volume (30 Days)
- SSKN 8.1K
- PMCB 14.2K
- Earning Date
- SSKN 11-13-2024
- PMCB 12-31-2024
- Dividend Yield
- SSKN N/A
- PMCB N/A
- EPS Growth
- SSKN N/A
- PMCB N/A
- EPS
- SSKN N/A
- PMCB 0.74
- Revenue
- SSKN $32,674,999.00
- PMCB N/A
- Revenue This Year
- SSKN $0.94
- PMCB N/A
- Revenue Next Year
- SSKN $11.30
- PMCB N/A
- P/E Ratio
- SSKN N/A
- PMCB $2.21
- Revenue Growth
- SSKN N/A
- PMCB N/A
- 52 Week Low
- SSKN $2.51
- PMCB $1.39
- 52 Week High
- SSKN $6.50
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- SSKN 42.17
- PMCB 45.24
- Support Level
- SSKN $2.96
- PMCB $1.60
- Resistance Level
- SSKN $3.15
- PMCB $1.69
- Average True Range (ATR)
- SSKN 0.12
- PMCB 0.11
- MACD
- SSKN -0.01
- PMCB -0.00
- Stochastic Oscillator
- SSKN 9.09
- PMCB 40.00
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.